

Christian Uprimny

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/281410/publications.pdf>

Version: 2024-02-01

31
papers

1,335
citations

567281

15
h-index

477307

29
g-index

31
all docs

31
docs citations

31
times ranked

1940
citing authors

#	ARTICLE	IF	CITATIONS
1	Cardiac sympathetic innervation in Parkinson's disease versus multiple system atrophy. <i>Clinical Autonomic Research</i> , 2022, 32, 103-114.	2.5	7
2	Impact of forced diuresis with furosemide and hydration on the halo artefact and intensity of tracer accumulation in the urinary bladder and kidneys on [68Ga]Ga-PSMA-11-PET/CT in the evaluation of prostate cancer patients. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 123-133.	6.4	13
3	Comparison of PET/CT imaging with [18F]FDOPA and cholecystokinin-2 receptor targeting [68Ga]Ga-DOTA-MGS5 in a patient with advanced medullary thyroid carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 935-936.	6.4	18
4	Somatostatin receptor 2 expression in nasopharyngeal cancer is induced by Epstein Barr virus infection: impact on prognosis, imaging and therapy. <i>Nature Communications</i> , 2021, 12, 117.	12.8	34
5	Long-Term Survival and Value of 18F-FDG PET/CT in Patients with Gastroenteropancreatic Neuroendocrine Tumors Treated with Second Peptide Receptor Radionuclide Therapy Course with 177Lu-DOTATATE. <i>Life</i> , 2021, 11, 198.	2.4	4
6	Early Injection of Furosemide Increases Detection Rate of Local Recurrence in Prostate Cancer Patients with Biochemical Recurrence Referred for ⁶⁸ Ga-PSMA-11 PET/CT. <i>Journal of Nuclear Medicine</i> , 2021, 62, 1550-1557.	5.0	13
7	Radiopharmaceutical Formulation and Preclinical Testing of 68Ga-Labeled DOTA-MGS5 for the Regulatory Approval of a First Exploratory Clinical Trial. <i>Pharmaceuticals</i> , 2021, 14, 575.	3.8	7
8	Comparison of Early Imaging and Imaging 60 min Post-Injection after Forced Diuresis with Furosemide in the Assessment of Local Recurrence in Prostate Cancer Patients with Biochemical Recurrence Referred for 68Ga-PSMA-11 PET/CT. <i>Diagnostics</i> , 2021, 11, 1191.	2.6	4
9	When cardiac surgery comes to its limits: a case report of pericardial mesothelioma invading the myocardium. <i>European Heart Journal - Case Reports</i> , 2021, 5, ytab237.	0.6	1
10	Organ-sparing surgery of penile cancer: higher rate of local recurrence yet no impact on overall survival. <i>World Journal of Urology</i> , 2020, 38, 417-424.	2.2	25
11	Visualization of malignant infiltration of the thoracic duct on 68Ga PSMA-11 PET/CT in a prostate cancer patient with biochemical recurrence. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 2042-2043.	6.4	0
12	The 68Ga/177Lu-theragnostic concept in PSMA-targeting of metastatic castration-resistant prostate cancer: impact of post-therapeutic whole-body scintigraphy in the follow-up. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 695-712.	6.4	37
13	Disseminated focal 18F-fluoro-deoxyglucose uptake upon granulocyte colony-stimulating factor therapy mimicking malignant bone infiltration: case report of a patient with very severe aplastic anemia. <i>Therapeutic Advances in Hematology</i> , 2020, 11, 204062072097761.	2.5	2
14	68Ga-PSMA-11 PET/CT: the rising star of nuclear medicine in prostate cancer imaging?. <i>Wiener Medizinische Wochenschrift</i> , 2019, 169, 3-11.	1.1	14
15	Current status of theranostics in prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 471-495.	6.4	115
16	Third-line treatment and 177Lu-PSMA radioligand therapy of metastatic castration-resistant prostate cancer: a systematic review. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 496-508.	6.4	152
17	Comparison of [68Ga]Ga-PSMA-11 PET/CT with [18F]NaF PET/CT in the evaluation of bone metastases in metastatic prostate cancer patients prior to radionuclide therapy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1873-1883.	6.4	41
18	68Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 941-949.	6.4	247

#	ARTICLE	IF	CITATIONS
19	Early PET imaging with [68]Ga-PSMA-11 increases the detection rate of local recurrence in prostate cancer patients with biochemical recurrence. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1647-1655.	6.4	41
20	Development of standardized image interpretation for 68Ga-PSMA PET/CT to detect prostate cancer recurrent lesions. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 1622-1635.	6.4	91
21	Early dynamic imaging in 68Ga-PSMA-11 PET/CT allows discrimination of urinary bladder activity and prostate cancer lesions. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 765-775.	6.4	69
22	Influence of the anterior notch in mobile-bearing UKA on patellofemoral radiotracer uptake and clinical outcome. <i>BMC Musculoskeletal Disorders</i> , 2017, 18, 532.	1.9	2
23	Current knowledge on the sensitivity of the 68Ga-somatostatin receptor positron emission tomography and the SUVmax reference range for management of pancreatic neuroendocrine tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 2072-2083.	6.4	31
24	Bi-insular cortical involvement in anti-NMDA-receptor encephalitis – a case report. <i>BMC Neurology</i> , 2016, 16, 130.	1.8	12
25	Direct comparison of 68Ga-DOTA-TOC and 18F-FDG PET/CT in the follow-up of patients with neuroendocrine tumour treated with the first full peptide receptor radionuclide therapy cycle. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016, 43, 1585-1592.	6.4	74
26	Thyroid carcinoma detected by incidental 18F-FDG uptake in a patient with progressive cerebellar syndrome. <i>Endocrine</i> , 2016, 51, 199-200.	2.3	5
27	68Ga-PSMA ligand PET versus 18F-NaF PET: evaluation of response to 223Ra therapy in a prostate cancer patient. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 362-363.	6.4	31
28	PET in lymphoma: who, when, how often, pitfalls?. <i>Memo - Magazine of European Medical Oncology</i> , 2015, 8, 43-47.	0.5	1
29	68Ga-PSMA PET/CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015, 42, 1284-1294.	6.4	234
30	Progressive multifocal leukoencephalopathy complicating untreated chronic lymphatic leukemia: Case report and review of the literature. <i>Journal of Clinical Virology</i> , 2014, 60, 424-427.	3.1	10
31	Fast Achievement Of a First Metabolic Complete Remission In a Lung Transplanted Patient With Multiple Comorbidities and CD30 Positive Anaplastic Large Cell Post-Transplant Lymphoproliferative Disorder (T-PTLD/ALCL) By Treatment With Brentuximab Vedotin Monotherapy. <i>Blood</i> , 2013, 122, 5124-5124.	1.4	0